Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody that targets the immunoglobulin-like domain-containing receptor 2 (ILDR2), exhibiting antitumor and immunosuppressive effects [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Bapotulimab (BAY-1905254) is a fully human IgG2 antibody that targets the immunoglobulin-like domain-containing receptor 2 (ILDR2), exhibiting antitumor and immunosuppressive effects [1]. |
In vitro | Bapotulimab inhibits the immunosuppressive effect of ILDR2 on T cell activation. This agent exhibits cross-reactivity between humans and mice, attributed to a 98% sequence identity in the extracellular domain between human and murine orthologs of ILDR2 [1]. Bapotulimab (BAY-1905254; at concentrations of 5, 25, 100, or 500 ng/mL) enhances T cell activation and promotes the proliferation of antigen-specific T cells in vitro [1]. |
In vivo | Bapotulimab (BAY-1905254; 10 mg/kg; intraperitoneal injection; administered on days 1 and 4) demonstrated a significant increase in antigen-specific T-cell proliferation and cytotoxicity [1]. |
Synonyms | BAY-1905254 |
Molecular Weight | N/A |
CAS No. | 2359413-58-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bapotulimab 2359413-58-2 BAY1905254 BAY 1905254 BAY-1905254 inhibitor inhibit